

2025-01-09
Press release



Enzymatica focuses on growth with new recruitment – Anna Söderlund joins as Senior Director Marketing & Sales

Enzymatica AB (publ) announces today that Anna Söderlund has joined as the new Senior Director Marketing & Sales. With over 25 years of experience in the Life Science industry, where she has held leading roles at global companies such as Pfizer and MSD, Anna brings solid expertise to the company.

– We are very pleased to welcome Anna Söderlund to Enzymatica. We are in an expansive phase with a strong focus on driving sales growth. Anna's long experience, strategic acumen, and commitment will be crucial to our continued success, says Claus Egstrand, CEO of Enzymatica.

Anna Söderlund holds a Master of Science in Economics from Linköping University and has previously successfully worked in key roles in marketing, sales and business development.

– I look forward to joining Enzymatica. ColdZyme has the potential to become the leading brand in the common cold segment in Sweden. Working with a product with such great potential and in such a dynamic company feels incredibly exciting, says Anna Söderlund.

The recruitment of Anna Söderlund strengthens Enzymatica's commitment to further expand and establish itself as a leading player in its segment. Anna Söderlund has taken up her position and is part of Enzymatica's Group Management.

For more information contact:

Claus Egstrand, CEO, Enzymatica AB

Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

About Enzymatica

Enzymatica AB develops and sells products that treat and relieve infections and symptoms in the upper respiratory tract. The products are based on Penzyme® technology, which includes marine enzymes with unique properties. The best-selling product is ColdZyme®, an oral spray for colds and cold-like symptoms in the upper respiratory tract. ColdZyme has been launched in roughly 30 markets on four continents. The strategy is to continue growing by developing more health products as well as strengthening the position in existing markets and expanding to more geographic markets via established partners. The company is headquartered in Lund and is listed on the Nasdaq First North Growth Market. Certified Adviser is Carnegie Investment Bank AB (publ).

For more information visit www.enzymatica.se